Kymera Therapeutics, Inc. - Common Stock (KYMR) stock analysis
KYMR · Kymera Therapeutics, Inc. - Common Stock
Latest recorded price: USD 125.85
Sector and industry: Healthcare · Biotechnology
Fiscal 2025 figures: revenue growth -5.7%, free cash flow margin -597.6%, ROIC -45.4%. The model flags 2 risk signals for this company (2 high severity).
Similar companies in Healthcare
- Ligand Pharmaceuticals Incorporated - Common Stock (LGND)
- Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)
- MeiraGTx Holdings plc (MGTX)
- Mirum Pharmaceuticals, Inc. - common stock (MIRM)
- MannKind Corporation (MNKD)
- Moderna, Inc. (MRNA)
- Maravai LifeSciences Holdings, Inc. (MRVI)
- NewAmsterdam Pharma Company N.V. (NAMS)